{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:43:01Z","timestamp":1780929781044,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00245453"],"award-info":[{"award-number":["RS-2023-00245453"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00245453"],"award-info":[{"award-number":["RS-2023-00245453"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Prime Pharm. Co."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00228-025-03813-x","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T19:05:46Z","timestamp":1740510346000},"page":"583-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Considerations of sex in bioequivalence assessments: does sex affect pharmacokinetic variability between evaluation formulations?"],"prefix":"10.1007","volume":"81","author":[{"given":"Ji-Hun","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"3813_CR1","volume-title":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations","author":"FDA","year":"2003","unstructured":"FDA (2003) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. Food and Drug Administration, Rockville"},{"issue":"3","key":"3813_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1742-7843.2009.00518.x","volume":"106","author":"JAG Morais","year":"2010","unstructured":"Morais JAG, Lobato MdR (2010) The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol 106(3):221\u2013225. https:\/\/doi.org\/10.1111\/j.1742-7843.2009.00518.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3813_CR3","doi-asserted-by":"publisher","unstructured":"Jalali RK, Rasaily D (2018) Generic drug and bioequivalence studies. In: Pharmaceutical medicine and translational clinical researched. Elsevier, pp327\u2013339. https:\/\/doi.org\/10.1016\/B978-0-12-802103-3.00021-3","DOI":"10.1016\/B978-0-12-802103-3.00021-3"},{"issue":"1","key":"3813_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1208\/s12248-021-00672-z","volume":"24","author":"M Bego","year":"2022","unstructured":"Bego M, Patel N, Cristofoletti R, Rostami-Hodjegan A (2022) Proof of concept in assignment of within-subject variability during virtual bioequivalence studies: propagation of intra-subject variation in gastrointestinal physiology using physiologically based pharmacokinetic modeling. AAPS J 24(1):21. https:\/\/doi.org\/10.1208\/s12248-021-00672-z","journal-title":"AAPS J"},{"issue":"2","key":"3813_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.12793\/tcp.2024.32.e10","volume":"32","author":"M Han","year":"2024","unstructured":"Han M, He Y, Liang J, Yao F, Lu P, Yan H, Wang J, Xie Y, Li X, Liu Q (2024) Pharmacokinetics and bioequivalence study of candesartan cilexetil tablet in Chinese volunteers under fasting condition: an open-label, randomized-sequence, 2-period crossover study. Transl Clin Pharmacol 32(2):107. https:\/\/doi.org\/10.12793\/tcp.2024.32.e10","journal-title":"Transl Clin Pharmacol"},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.1007\/s00210-024-03190-9","volume":"397","author":"S-M Lee","year":"2024","unstructured":"Lee S-M, Jang J-H, Jeong S-H (2024) Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach. Naunyn Schmiedebergs Arch Pharmacol 397:8311\u20138347. https:\/\/doi.org\/10.1007\/s00210-024-03190-9","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3813_CR7","doi-asserted-by":"publisher","first-page":"153733","DOI":"10.1016\/j.tox.2024.153733","volume":"502","author":"S-H Jeong","year":"2024","unstructured":"Jeong S-H, Jang J-H, Cho H-Y, Lee Y-B (2024) Sex differences in 4-tert-octylphenol toxicokinetics: Exploration of sex as an effective covariate through an in vivo modeling approach. Toxicology 502:153733. https:\/\/doi.org\/10.1016\/j.tox.2024.153733","journal-title":"Toxicology"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s11095-011-0651-y","volume":"29","author":"V Karalis","year":"2012","unstructured":"Karalis V, Symillides M, Macheras P (2012) Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA. Pharm Res 29:1066\u20131077. https:\/\/doi.org\/10.1007\/s11095-011-0651-y","journal-title":"Pharm Res"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1007\/s11095-008-9645-9","volume":"25","author":"V Karalis","year":"2008","unstructured":"Karalis V, Macheras P, Van Peer A, Shah VP (2008) Bioavailability and bioequivalence: focus on physiological factors and variability. Pharm Res 25:1956\u20131962. https:\/\/doi.org\/10.1007\/s11095-008-9645-9","journal-title":"Pharm Res"},{"issue":"1","key":"3813_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinthera.2016.11.024","volume":"39","author":"M Ibarra","year":"2017","unstructured":"Ibarra M, V\u00e1zquez M, Fagiolino P (2017) Sex effect on average bioequivalence. Clin Ther 39(1):23\u201333. https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.024","journal-title":"Clin Ther"},{"issue":"7","key":"3813_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1055\/s-0031-1296880","volume":"55","author":"S Almeda","year":"2005","unstructured":"Almeda S, Filipe A, Almeida A, Wong H, Caparr\u00f3s N, Tanguay M (2005) Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Arzneim Forsch Drug Res 55(7):414\u2013419. https:\/\/doi.org\/10.1055\/s-0031-1296880","journal-title":"Arzneim Forsch Drug Res"},{"issue":"2","key":"3813_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1055\/s-0031-1296704","volume":"56","author":"S Almeida","year":"2006","unstructured":"Almeida S, Filipe A, Almeida A, Gich I, Antonijoan R, Puntes M, Barbanoj M, Caturla MC (2006) Comparative study on the bioequivalence of two formulations of pravastatin. Arzneim Forsch Drug Res 56(2):70\u201375. https:\/\/doi.org\/10.1055\/s-0031-1296704","journal-title":"Arzneim Forsch Drug Res"},{"issue":"3","key":"3813_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1177\/009286159502900304","volume":"29","author":"M-L Chen","year":"1995","unstructured":"Chen M-L, Williams RL (1995) Women in bioavailability\/bioequivalence trials\u2014A regulatory perspective. Drug Inf J 29(3):813\u2013820. https:\/\/doi.org\/10.1177\/009286159502900304","journal-title":"Drug Inf J"},{"issue":"5","key":"3813_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1067\/mcp.2000.111184","volume":"68","author":"ML Chen","year":"2000","unstructured":"Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL (2000) Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68(5):510\u2013521. https:\/\/doi.org\/10.1067\/mcp.2000.111184","journal-title":"Clin Pharmacol Ther"},{"key":"3813_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1874073100701010007","volume":"1","author":"P Fagiolino","year":"2007","unstructured":"Fagiolino P, Gonz\u00e1lez N, V\u00e1zquez M, Eiraldi R (2007) Itraconazole bioequivalence revisited: Influence of gender on highly variable drugs. Open Drug Metab J 1:7\u201313. https:\/\/doi.org\/10.2174\/1874073100701010007","journal-title":"Open Drug Metab J"},{"key":"3813_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2389","author":"M Gundeti","year":"2024","unstructured":"Gundeti M, Murthy A, Jamdade S, Ahmed T (2024) Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling\u2013A case study of dextromethorphan modified release tablets. Biopharm Drug Dispos. https:\/\/doi.org\/10.1002\/bdd.2389","journal-title":"Biopharm Drug Dispos"},{"key":"3813_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejps.2016.02.001","volume":"85","author":"M Ibarra","year":"2016","unstructured":"Ibarra M, Magallanes L, Lorier M, V\u00e1zquez M, Fagiolino P (2016) Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Eur J Pharm Sci 85:106\u2013111. https:\/\/doi.org\/10.1016\/j.ejps.2016.02.001","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"3813_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.2012.233","volume":"93","author":"G Koren","year":"2013","unstructured":"Koren G, Nordeng H, MacLeod S (2013) Gender differences in drug bioequivalence: time to rethink practices. Clin Pharmacol Ther 93(3):260\u2013262. https:\/\/doi.org\/10.1038\/clpt.2012.233","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3813_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.29413\/ABS.2018-3.5.15","volume":"3","author":"D Romodanovsky","year":"2018","unstructured":"Romodanovsky D, Goryachev D, Khokhlov A, Miroshnikov A (2018) Influence of sex differences on pharmacokinetics of drugs within the framework of bioequivalence studies of generic medicinal products. Acta Biomed Sci 3(5):94\u2013105. https:\/\/doi.org\/10.29413\/ABS.2018-3.5.15","journal-title":"Acta Biomed Sci"},{"key":"3813_CR20","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1023\/A:1013319408893","volume":"18","author":"M-L Chen","year":"2001","unstructured":"Chen M-L, Shah V, Patnaik R, Adams W, Hussain A, Conner D, Mehta M, Malinowski H, Lazor J, Huang S-M (2001) Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 18:1645\u20131650. https:\/\/doi.org\/10.1023\/A:1013319408893","journal-title":"Pharm Res"},{"issue":"4","key":"3813_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wics.1310","volume":"6","author":"SC Chow","year":"2014","unstructured":"Chow SC (2014) Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat 6(4):304\u2013312. https:\/\/doi.org\/10.1002\/wics.1310","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"key":"3813_CR22","unstructured":"EMA (2017) Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action (EMA\/CHMP\/CVMP\/QWP\/336031\/2017).\u00a0European Medicines Agency (EMA), London, UK"},{"key":"3813_CR23","unstructured":"FDA (2018) Waiver of in vivo bioavailability and bioequivalence studies for immediaterelease solid oral dosage forms base on a Biopharmaceutics Classification System. Maryland, EUA, 2017:19"},{"issue":"11","key":"3813_CR24","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.3390\/biomedicines11113021","volume":"11","author":"S-H Jeong","year":"2023","unstructured":"Jeong S-H, Jang J-H, Lee Y-B (2023) Exploring differences in pharmacometrics of rabeprazole between genders via population pharmacokinetic-pharmacodynamic modeling. Biomedicines 11(11):3021. https:\/\/doi.org\/10.3390\/biomedicines11113021","journal-title":"Biomedicines"},{"issue":"1","key":"3813_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/pharmaceutics16010146","volume":"16","author":"S-H Jeong","year":"2024","unstructured":"Jeong S-H, Jang J-H, Lee Y-B (2024) Is gender an important factor in the precision medicine approach to levocetirizine? Pharmaceutics 16(1):146. https:\/\/doi.org\/10.3390\/pharmaceutics16010146","journal-title":"Pharmaceutics"},{"key":"3813_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/11318040-000000000-00000","volume":"48","author":"L Tothfalusi","year":"2009","unstructured":"Tothfalusi L, Endrenyi L, Arieta AG (2009) Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet 48:725\u2013743. https:\/\/doi.org\/10.2165\/11318040-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3813_CR27","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/bcp.14055","volume":"85","author":"A Ring","year":"2019","unstructured":"Ring A, Lang B, Kazaroho C, Labes D, Schall R, Sch\u00fctz H (2019) Sample size determination in bioequivalence studies using statistical assurance. Br J Clin Pharmacol 85(10):2369\u20132377. https:\/\/doi.org\/10.1111\/bcp.14055","journal-title":"Br J Clin Pharmacol"},{"key":"3813_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF00314794","volume":"38","author":"G Pabst","year":"1990","unstructured":"Pabst G, Jaeger H (1990) Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 38:5\u201310. https:\/\/doi.org\/10.1007\/BF00314794","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3813_CR29","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/sim.6834","volume":"35","author":"J Munoz","year":"2016","unstructured":"Munoz J, Alcaide D, Oca\u00f1a J (2016) Consumer\u2019s risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs. Stat Med 35(12):1933\u20131943. https:\/\/doi.org\/10.1002\/sim.6834","journal-title":"Stat Med"},{"issue":"21","key":"3813_CR30","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/sim.4286","volume":"30","author":"A Dubois","year":"2011","unstructured":"Dubois A, Lavielle M, Gsteiger S, Pigeolet E, Mentr\u00e9 F (2011) Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Stat Med 30(21):2582\u20132600. https:\/\/doi.org\/10.1002\/sim.4286","journal-title":"Stat Med"},{"issue":"4","key":"3813_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/cp.1999.v66.a101209","volume":"66","author":"GJP Singh","year":"1999","unstructured":"Singh GJP, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, Pershing LK (1999) Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther 66(4):346\u2013357. https:\/\/doi.org\/10.1053\/cp.1999.v66.a101209","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03813-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:19:36Z","timestamp":1742419176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03813-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03813-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical studies were conducted in accordance with the Rules of Good Clinical Practice and the revised Declaration of Helsinki for Biomedical Research with Human Subjects. All subjects had no prior history of hypersensitivity or related reactions to steroid drugs and were physically normal. To confirm their physical health, all subjects underwent a physical examination, clinical screening, complete blood count, urinalysis, and blood chemistry analyses prior to participating in this clinical study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects provided written informed consent prior to their participation in bioequivalence and pharmacokinetic studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All data were anonymized, and participants were informed that the results of this study may be subject to publication and presentation in meetings.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The clinical trial protocols were thoroughly reviewed and officially approved by the Ministry of Food and Drug Safety (Cheongju-si, Republic of Korea). The approval number of the trial for levocetirizine was MB22-013. The approval number of the trial for rabeprazole was MB22-002.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}